Artículos por temáticas

Objective biomarkers of balance and gait for Parkinson's disease using body-worn sensors.

Horak FB, Mancini M.

Mov Disord. 2013 Sep 15;28(11):1544-51. doi: 10.1002/mds.25684. Review.

Characterizing freezing of gait in Parkinson's disease: models of an episodic phenomenon.

Nieuwboer A, Giladi N.

Mov Disord. 2013 Sep 15;28(11):1509-19. doi: 10.1002/mds.25683. Review.

Time perception impairs sensory-motor integration in Parkinson's disease.

Lucas M, Chaves F, Teixeira S, Carvalho D, Peressutti C, Bittencourt J, Velasques B, Menéndez-González M, Cagy M, Piedade R, Nardi AE, Machado S, Ribeiro P, Arias-Carrión O.

Int Arch Med. 2013 Oct 16;6(1):39. doi: 10.1186/1755-7682-6-39.

Functional or somatoform disorders in Parkinson's disease?

Onofrj M.

Mov Disord. 2013 Nov;28(13):1907. doi: 10.1002/mds.25714. No abstract available.

Endonuclease G mediates α-synuclein cytotoxicity during Parkinson's disease.

Büttner S, Habernig L, Broeskamp F, Ruli D, Vögtle FN, Vlachos M, Macchi F, Küttner V, Carmona-Gutierrez D, Eisenberg T, Ring J, Markaki M, Taskin AA, Benke S, Ruckenstuhl C, Braun R, Van den Haute C,

EMBO J. 2013 Nov 27;32(23):3041-54. doi: 10.1038/emboj.2013.228.

Deep brain stimulation for Parkinson's disease with early motor complications.

[No authors listed]

Med Lett Drugs Ther. 2013 Oct 14;55(1427):81-2. No abstract available.

NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Decressac M, Volakakis N, Björklund A, Perlmann T.

Nat Rev Neurol. 2013 Nov;9(11):629-36. doi: 10.1038/nrneurol.2013.209. Review.

Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog).

Isella V, Mapelli C, Morielli N, De Gaspari D, Siri C, Pezzoli G, Antonini A, Poletti M, Bonuccelli U, Picchi L, Napolitano A, Vista M, Veglia M, Piamarta F, Grassi F, Appollonio IM.

Funct Neurol. 2013 Apr-May;28(2):121-5. doi: 10.11138/FNeur/2013.28.2.121.

Non-genetic factors associated with the risk of Parkinson's disease in Iranian patients.

Hosseini Tabatabaei N, Babakhani B, Hosseini Tabatabaei A, Vahabi Z, Soltanzadeh A.

Funct Neurol. 2013 Apr-May;28(2):107-13. doi: 10.11138/FNeur/2013.28.2.107.

Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.

Brusa L, Orlacchio A, Stefani A, Galati S, Pierantozzi M, Iani C, Mercuri NB.

Funct Neurol. 2013 Apr-May;28(2):101-5. doi: 10.11138/FNeur/2013.28.2.101.

Differences between conventional and nonconventional MRI techniques in Parkinson's disease.

Baglieri A, Marino MA, Morabito R, Di Lorenzo G, Bramanti P, Marino S.

Funct Neurol. 2013 Apr-May;28(2):73-82. doi: 10.11138/FNeur/2013.28.2.073. Review.

Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.

Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I; LABS-PD investigators..

Mov Disord. 2013 Dec;28(14):1980-6. doi: 10.1002/mds.25671.

Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.

Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT.

Mov Disord. 2013 Dec;28(14):1972-9. doi: 10.1002/mds.25655.

Dementia in Parkinson's disease: usefulness of the pill questionnaire.

Martinez-Martin P.

Mov Disord. 2013 Nov;28(13):1832-7. doi: 10.1002/mds.25649.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Parkinson Study Group..

Mov Disord. 2013 Nov;28(13):1823-31. doi: 10.1002/mds.25639.